2. Search Result
Search Result
Results for "

nonhuman

" in MedChemExpress (MCE) Product Catalog:

51

Inhibitors & Agonists

3

Peptides

10

Inhibitory Antibodies

4

Natural
Products

1

Isotope-Labeled Compounds

5

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99575
    Tarlatamab
    1 Publications Verification

    AMG-757

    		 Notch Inflammation/Immunology Cancer
    Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .
    Tarlatamab
  • HY-P1717
    AMY-101
    Maximum Cited Publications
    7 Publications Verification

    Cp40

    		 Complement System SARS-CoV Inflammation/Immunology
    AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .
    AMY-101
  • HY-153810
    Mosnodenvir

    JNJ-1802

    		 Virus Protease Flavivirus Dengue Virus Infection
    Mosnodenvir (JNJ-1802) is an orally active pan serotype dengue virus (DENV) inhibitor, with EC50 values ranging from 0.057 to 11 nM for four dengue virus (DENV) serotypes. Mosnodenvir blocks viral replication by inhibiting the formation of complexes between two viral proteins, nonstructural protein 3 (NS3) and NS4B, thereby preventing the formation of new viral RNA. Mosnodenvir exhibits picomolar to nanomolar antiviral activity in vitro and has antiviral efficacy in mice and non-human primates .
    Mosnodenvir
  • HY-128965
    N-Glycolylneuraminic acid

    NeuGc; GcNeu

    		 Influenza Virus Endogenous Metabolite Infection Cancer
    N-Glycolylneuraminic acid is a nonhuman sialic acid molecule synthesized in pigs but not in humans. N-Glycolylneuraminic acid works as a decoy receptor of N-Glycolylneuraminic acid-binding influenza A viruses (IAVs) .
    N-Glycolylneuraminic acid
  • HY-P1717B
    AMY-101 acetate
    Maximum Cited Publications
    7 Publications Verification

    Cp40 acetate

    		 Complement System SARS-CoV Inflammation/Immunology
    AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 acetate (Cp40 acetate) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .
    AMY-101 acetate
  • HY-P1717A
    AMY-101 TFA
    Maximum Cited Publications
    7 Publications Verification

    Cp40 TFA

    		 Complement System SARS-CoV Inflammation/Immunology
    AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .
    AMY-101 TFA
  • HY-152148
    JZP-MA-11

    		MAGL Neurological Disease
    JZP-MA-11 is a brain-penetrant positron emission tomography (PET) ligand targeting the brain endocannabinoid α/β-hydrolase domain 6 (ABHD6) enzyme. JZP-MA-11 selectively inhibits ABHD6 with an IC50 value of 126 nM. [18F]JZP-MA-11 has the potential for preclinical evaluation targeting the brain ABHD6 in mice and nonhuman primate (NHP) .
    JZP-MA-11
  • HY-P99302
    Lulizumab

    BMS-931699 Antibody

    		 CD28 Inflammation/Immunology
    Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is an anti-CD28 domain antibody antagonist. Lulizumab inhibits T-cell activation by selectively targeting the CD28 signal. In a sensitized non-human primate kidney transplantation model, when combined with Carfilzomib (HY-10455), Lulizumab can regulate immune cells and prolong the survival time of the graft .
    Lulizumab
  • HY-135714
    Bavarostat

    EKZ-001

    		 HDAC Microtubule/Tubulin Neurological Disease Cancer
    Bavarostat (EKZ-001) is a blood-brain barrier-permeable, potent HDAC6 inhibitor and PET radiotracer, with an IC50 as low as 17 nM against human HDAC6. Bavarostat can be labeled with 18F and used as a probe to map HDAC6 distribution and measure target occupancy in the brains of non-human primates. Bavarostat also selectively modulates tubulin acetylation, but not histone acetylation. Bavarostat is applicable for research on Alzheimer's disease, other neurodegenerative disorders, and cancers .
    Bavarostat
  • HY-P991069
    VRC-01

    		HIV Infection
    VRC-01 is a broadly neutralizing IgG1 monoclonal antibody that targets HIV-1 envelope glycoprotein gp120 Protein. VRC-01 blocks HIV-1 viral entry by mimicking CD4 receptor interaction with HIV-1 gp120 and neutralizes broad HIV-1 clades. VRC-01 can be used for the research of HIV-1 infection .
    VRC-01
  • HY-P991400
    GSK1995057

    		TNF Receptor Apoptosis Interleukin Related NF-κB JNK p38 MAPK Inflammation/Immunology
    GSK1995057 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK1995057 selectively binds to TNFR1, blocks the binding of TNF-α and LT-α, and does not interfere with TNFR2 signaling. GSK1995057 inhibits the activation of NF-κB, JNK and MAPK pathways, alleviates apoptosis (apoptosis) and inflammatory responses (inhibiting IL-1β, IL-6, IL-10, TNF-α), and prevents viability loss of human nucleus pulposus cells. GSK1995057 inhibits the expression of cytokines and neutrophil adhesion molecules in human pulmonary microvascular endothelial cell monolayers, and reduces inflammatory responses and lung injury symptoms in non-human primates. GSK1995057 forms complexes with HAVH autoantibodies, thereby activating TNFR1 and triggering the release of cytokines and IL-8 in human cells. GSK1995057 can be used in research related to intervertebral disc degeneration and acute lung injury .
    GSK1995057
  • HY-101422
    GAL-021
    5+ Cited Publications

    		 Potassium Channel Inflammation/Immunology
    GAL-021 is a potent BKCa-channel blocker. GAL-021 inhibits KCa1.1 in GH3 cells. GAL-021 is a novel breathing control modulator that is based on selective modification of the almitrine pharmacophore. GAL-021 increases minute ventilation in rats and non-human primates .
    GAL-021
  • HY-112692
    AT-121

    		Opioid Receptor Neurological Disease
    AT-121 is a bifunctional nociception and mu opioid receptor agonist, with Kis of 3.67 and 16.49 nM, respectively. AT-121 is a safe, non-addictive analgesic, and shows antinociceptive and antiallodynic effects .
    AT-121
  • HY-P991023
    Safimestomig

    6MW3211

    		 CD47 PD-1/PD-L1 Cancer
    Safimestomig (6MW3211) is an CD47/PD-L1-targeting bispecific antibody. Safimestomig blocks CD47-mediated 'don't eat me' signaling and selectively binds to CD47 on tumor cells. Safimestomig blocks PD-L1-mediated immune checkpoint signaling. Safimestomig can be used for the research of cancer .
    Safimestomig
  • HY-157802
    LTGO-33

    		Sodium Channel Neurological Disease
    LTGO-33 is a potent and selective voltage-gated sodium channel NaV1.8 inhibitor. LTGO-33 inhibits NaV1.8 in the nM potency range and exhibits over 600-fold selectivity against human NaV1.1-NaV1.7 and NaV1.9. LTGO-33 exhibits state-independent inhibition with similar potencies on channels in the closed and inactivated conformations. LTGO-33 inhibits native TTX-R NaV1.8 currents in non-human primate and human DRG neurons, where it reduces action potential firing. LTGO-33 can be used for pain disorders research .
    LTGO-33
  • HY-113266
    Valerylcarnitine
    2 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    Valerylcarnitine is an endogenous metabolite, belonging to the short-chain acylcarnitines. Valerylcarnitine acts as a metabolomic biomarker for ionizing radiation exposure in nonhuman primates. Valerylcarnitine can be used for the research of type 1 diabetes .
    Valerylcarnitine
  • HY-118944
    L-748328

    		Adrenergic Receptor Endocrinology
    L-748328 is a potent and selective human β3-adrenergic receptor antagonist. L-748328 has a Ki of 3.7 nM against human cloned β3-AR expressed in Chinese hamster ovary (CHO) cells. In addition, L-748328 inhibits the lipolytic response induced by the β3-AR agonist L-742791 in isolated non-human primate adipocytes .
    L-748328
  • HY-158821A
    ISTH0036 sodium

    		TGF-beta/Smad Neurological Disease
    ISTH0036 sodium is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 sodium suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 sodium exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 sodium can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases .
    ISTH0036 sodium
  • HY-115726
    FRM-024

    		γ-secretase Amyloid-β Neurological Disease
    FRM-024 is a central nervous system-penetrant, orally active γ-secretase modulator and Aβ42 lowering agent. FRM-024 is used for the research of familial Alzheimer's disease .
    FRM-024
  • HY-118356
    WIN 62,577

    		Neurokinin Receptor mAChR Neurological Disease
    WIN 62,577 is a rat-specific, but non-human, NK1 receptor antagonist. WIN 62,577 interacts with M1-M4 mAChRs and is an allosteric enhancer of acetylcholine affinity targeting the M3 receptor.
    WIN 62,577
  • HY-120464
    PF-05212377

    SAM-760

    		 5-HT Receptor Neurological Disease
    PF-05212377 (SAM-760) is an inhibitor for serotonin receptor 5-HT6. PF-05212377 is a substrate for P-gp/non-BCRP human transporter. PF-05212377 exhibits blood brain barrier permeability in non-human primates. PF-05212377 can be used for Alzheimer’s Disease research .
    PF-05212377
  • HY-112692A
    AT-121 hydrochloride

    		Opioid Receptor Neurological Disease
    AT-121 hydrochloride is a bifunctional nociception and mu opioid receptor agonist, with Kis of 3.67 and 16.49 nM, respectively. AT-121 hydrochloride is a safe, non-addictive analgesic, and shows antinociceptive and antiallodynic effects .
    AT-121 hydrochloride
  • HY-158821
    ISTH0036

    		TGF-beta/Smad Neurological Disease
    ISTH0036 is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases .
    ISTH0036
  • HY-179227
    HDAC6 ligand-7

    		HDAC Neurological Disease
    HDAC6 ligand-7 (Compound 16a) is a positron emission tomography (PET) tracer for the deacetylase 6 (HDAC6) enzyme with a Kd value of 1.66 nM. HDAC6 ligand-7 exhibits excellent HDAC6 inhibitory activity, with IC50 values of 2.7 and 3.7 nM for hHDAC6 and mHDAC6, respectively, and has high selectivity for HDAC1/4/7/8. HDAC6 ligand-7 after being radioactively labeled with fluorine-18, [¹⁸F]HDAC6 ligand-7 shows varying degrees of radioactive uptake in PET, which can reflect the specific binding to HDAC6. HDAC6 ligand-7 can be used for the study of HDAC6 imaging .
    HDAC6 ligand-7
  • HY-P991479
    Amtabafusp alfa

    GS-8588

    		 HIV CD3 Infection
    Amtabafusp alfa (GS-8588) is an envelope-targeting bispecific T-cell engager for HIV treatment. Amtabafusp alfa redirects effector T cells by binding to CD3 via a humanized anti-CD3 Fab domain and to HIV envelope proteins via an engineered CD4 domain 1 variant. Amtabafusp alfa exhibits potent, broad-spectrum activity against a variety of HIV isolates and specifically kills HIV-infected cells. Amtabafusp alfa can be used for research on HIV infection .
    Amtabafusp alfa
  • HY-113266R
    Valerylcarnitine (Standard)

    		Reference Standards Endogenous Metabolite Metabolic Disease
    Valerylcarnitine (Standard) is the analytical standard of Valerylcarnitine. Valerylcarnitine is an endogenous metabolite, belonging to the short-chain acylcarnitines. Valerylcarnitine acts as a metabolomic biomarker for ionizing radiation exposure in nonhuman primates. Valerylcarnitine can be used for the research of type 1 diabetes .
    Valerylcarnitine (Standard)
  • HY-113266S
    Valerylcarnitine-d9

    C5:0 L-carnitine-d9

    		 Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    Valerylcarnitine-d9 (C5:0 L-carnitine-d9) is the deuterium labeled Valerylcarnitine (HY-113266). Valerylcarnitine is an endogenous metabolite, belonging to the short-chain acylcarnitines. Valerylcarnitine acts as a metabolomic biomarker for ionizing radiation exposure in nonhuman primates. Valerylcarnitine can be used for the research of type 1 diabetes .
    Valerylcarnitine-d9
  • HY-163075
    SYB4

    		Sigma Receptor Others
    SYB4 (compound 5) is a PET tracer which suitable for imaging the Sigma-2 Receptor in the brain of nonhuman primates .
    SYB4
  • HY-117527
    L742791

    		Adrenergic Receptor Metabolic Disease
    L742791 is a β3-AR agonist. L742791 elicits lipolytic response in isolated nonhuman primate adipocytes .
    L742791
  • HY-103491
    PF-06462894

    		iGluR Neurological Disease
    PF-06462894 is an alkyne-lacking metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator profiled in both rat and nonhuman primates .
    PF-06462894
  • HY-P99911
    Efizonerimod alfa

    MEDI-6383

    		 Orexin Receptor (OX Receptor) Inflammation/Immunology Cancer
    Efizonerimod alfa (MEDI-6383) is a recombinant human OX40L IgG4P Fc fusion protein that assembles into a hexameric structure and exerts potent agonist activity upon binding to OX40. The activity of Efizonerimod alfa is enhanced by Fcγ receptor-mediated aggregation. Efizonerimod alfa binds to OX40 on the surface of activated T cells, induces NF-κB promoter activity in OX40-expressing T cells, and triggers the production of Th1-type cytokines, T cell proliferation, and resistance to regulatory T cell (Treg)-mediated suppression. Efizonerimod alfa enhances the cytolytic activity of tumor-reactive T cells and slows tumor growth in immunodeficient mice. Efizonerimod alfa induces the proliferation of CD4, CD8, and B cells in the peripheral blood of healthy non-human primates. Efizonerimod alfa can be used in the research of advanced solid malignancies and melanoma .
    Efizonerimod alfa
  • HY-128965R
    N-Glycolylneuraminic acid (Standard)

    NeuGc (Standard); GcNeu (Standard)

    		 Reference Standards Influenza Virus Endogenous Metabolite Infection Cancer
    N-Glycolylneuraminic acid (Standard) is the analytical standard of N-Glycolylneuraminic acid. This product is intended for research and analytical applications. N-Glycolylneuraminic acid is a nonhuman sialic acid molecule synthesized in pigs but not in humans. N-Glycolylneuraminic acid works as a decoy receptor of N-Glycolylneuraminic acid-binding influenza A viruses (IAVs) .
    N-Glycolylneuraminic acid (Standard)
  • HY-163486
    Antituberculosis agent-10

    		Bacterial Infection
    Antituberculosis agent-10 (Compound 9) has excellent antibacterial activity against Mycobacterium tuberculosis (MIC = 0.3 μM). Antituberculosis agent-10 inhibits protein synthesis by targeting the 50S ribosomal subunit of the bacterium, thus exerting its antibacterial effect. Antituberculosis agent-10 is orally active .
    Antituberculosis agent-10
  • HY-P991467
    RG-7258

    		Interleukin Related Inflammation/Immunology
    RG-7258 is a human monoclonal antibody (mAb) targeting CRLF2. RG-7258 blocks dendritic cell activation and mast cell cytokine release. RG-7258 reduces Th2 inflammation in a non-human primate model of allergic lung inflammation. RG-7258 can be used in asthma research .
    RG-7258
  • HY-148698
    2MD

    		VD/VDR Others
    2MD is an orally active vitamin D analog. 2MD stimulates periosteal bone formation and decreases trabecular bone resorption. Thus 2MD restores trabecular and cortical bone mass and strength. 2MD also regulates intraocular pressure (IOP)-relative genes and reduces IOP in non-human primates .
    2MD
  • HY-101422A
    GAL-021 sulfate

    		Potassium Channel Inflammation/Immunology
    GAL-021 sulfate is a potent BKCa-channel blocker. GAL-021 sulfate inhibits KCa1.1 in GH3 cells. GAL-021 sulfate is a novel breathing control modulator that is based on selective modification of the almitrine pharmacophore. GAL-021 sulfate increases minute ventilation in rats and non-human primates .
    GAL-021 sulfate
  • HY-135493
    RS-56812

    		5-HT Receptor Neurological Disease
    RS-56812 is a partial agonist of the 5-HT3 receptor. RS-56812 significantly enhances the propulsive peristalsis of the colon. RS-56812 indirectly enhances cholinergic neurotransmission and improves the working memory performance of non-human primates. RS-56812 is used in research on diarrhea/colon peristalsis and cognitive disorders (such as Alzheimer's disease) .
    RS-56812
  • HY-117637
    ALS-I-41

    		Oxytocin Receptor Neurological Disease
    ALS-I-41 is a novel, potent and selective oxytocin receptor antagonist with the potential to modulate biological activities related to social behavior and mental disorders. ALS-I-41 is being evaluated for behavioral pharmacology experiments in non-human primates and can be administered via intranasal or intramuscular injection. The central nervous system penetration and metabolic rate of ALS-I-41 were studied by mass spectrometry analysis in cerebrospinal fluid and plasma of macaque monkeys .
    ALS-I-41
  • HY-181351
    PSN09

    		Glycine Receptor (GlyR) 5-HT Receptor Neurological Disease
    PSN09 is a blood-brain barrier-permeable agonist of PSAM 4-GlyR and PSAM 4-5-HT3 receptors with high affinity. 18F-labeled PSN09 serves as a radiotracer for PET imaging in non-human primates .
    PSN09
  • HY-P991921
    TNX-1500

    		TNF Receptor Fc Receptor (FcR) Cardiovascular Disease Endocrinology
    TNX-1500 is a crystallizable fragment-modified anti-CD154 antibody. TNX-1500 contains the hu5c8 fragment antigen-binding (Fab) domain from Ruplizumab (HY-P99315) and an IgG4 Fc region engineered to reduce FcγRIIa binding. TNX-1500 has significantly weaker binding affinity to FcγRI, FcγRIIaH, FcγRIIbF, FcγRIIIaF, and FcγRIIIaV compared to hu5c8 (Kd values: 8.7 nM, 7100 nM, 4900 nM, 8000 nM, 6000 nM respectively). TNX-1500 prolongs nonhuman primate renal allograft survival, prolongs nonhuman primate cardiac allograft survival. TNX-1500 can be used for the research of allograft rejection [1] [2].
    TNX-1500
  • HY-182944
    GATT-44

    		GABA Receptor Neurological Disease
    GATT-44 is a blood-brain barrier-permeable, selective GABA transporter 1 (GAT-1) ligand with an IC50 of 126 nM. GATT-44 shows selectivity for GAT-2, GAT-3 and BGT-1 subtypes, and undergoes copper-mediated 18F-radiofluorination. The radiolabeled GATT-44 ([ 18F]GATT-44) exhibits brain uptake, metabolic stability and high GAT-1 binding specificity in non-human primates. GATT-44 is applicable for research on neurodegenerative and neuropsychiatric diseases .
    GATT-44
  • HY-106021
    Tasidotin

    ILX651 free base

    		 Microtubule/Tubulin Prolyl Endopeptidase (PREP) Cancer
    Tasidotin (ILX651 free base) is a tubulin inhibitor and competitive Prolyl Endopeptidase (PREP) inhibitor, with an IC50 of 10 μM against bovine tubulin. Tasidotin exhibits high cerebrospinal fluid penetration in non-human primates. Tasidotin antagonizes microtubule assembly and induces an extended assembly lag phase, thereby inhibiting mitosis and cell proliferation, and exerts cytotoxic and oncolytic effects on cancer cells. Tasidotin is metabolized into polypeptides and proline inside cells, and its in vivo metabolism is mediated by prolyl endopeptidase. Tasidotin can be applied in research related to Burkitt's lymphoma, breast cancer, leukemia, melanoma, central nervous system malignancies and various solid tumors .
    Tasidotin
  • HY-101422R
    GAL-021 (Standard)

    		Potassium Channel Reference Standards Inflammation/Immunology
    GAL-021 (Standard) is the analytical standard of GAL-021 (HY-101422). This product is intended for research and analytical applications. GAL-021 is a potent BKCa-channel blocker. GAL-021 inhibits KCa1.1 in GH3 cells. GAL-021 is a novel breathing control modulator that is based on selective modification of the almitrine pharmacophore. GAL-021 increases minute ventilation in rats and non-human primates .
    GAL-021 (Standard)
  • HY-121621
    RO5101576

    		Endogenous Metabolite Inflammation/Immunology
    RO5101576 is a potent LTB4 receptor antagonist with activity to inhibit LTB4-induced calcium mobilization and chemotaxis of human neutrophils. RO5101576 significantly attenuated LTB4-induced pulmonary eosinophilia in guinea pigs. RO5101576 inhibited allergen- and ozone-induced pulmonary neutrophilia in nonhuman primates with efficacy comparable to that of budesonide. RO5101576 had no effect on LPS-induced neutrophilia in guinea pigs and cigarette smoke-induced neutrophilia in mice and rats. RO5101576 performed well in toxicology studies and was well tolerated .
    RO5101576
  • HY-182317
    (+)-Mosnodenvir

    		Drug Isomer Dengue Virus Infection
    (+)-Mosnodenvir is an isomer of Mosnodenvir (HY-153810). Mosnodenvir (JNJ-1802) is an orally active pan serotype dengue virus (DENV) inhibitor, with EC50 values ranging from 0.057 to 11 nM for four dengue virus (DENV) serotypes. Mosnodenvir blocks viral replication by inhibiting the formation of complexes between two viral proteins, nonstructural protein 3 (NS3) and NS4B, thereby preventing the formation of new viral RNA. Mosnodenvir exhibits picomolar to nanomolar antiviral activity in vitro and has antiviral efficacy in mice and non-human primates .
    (+)-Mosnodenvir
  • HY-158821B
    ISTH0036 sodium scrambled negative control

    		TGF-beta/Smad Neurological Disease
    ISTH0036 sodium scrambled negative control is the sequence scrambled negative control of ISTH0036 sodium (HY-158821A). ISTH0036 sodium is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 sodium suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 sodium exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 sodium can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases.
    ISTH0036 sodium scrambled negative control
  • HY-158821D
    Cy3 labled ISTH0036 sodium

    		Fluorescent Dye TGF-beta/Smad Neurological Disease
    Cy3 labled ISTH0036 sodium is a Cy3 labled ISTH0036 sodium (HY-158821A). ISTH0036 sodium is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 sodium suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 sodium exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 sodium can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases.
    Cy3 labled ISTH0036 sodium
  • HY-158821C
    FAM labled ISTH0036 sodium

    		Fluorescent Dye TGF-beta/Smad Neurological Disease
    FAM labled ISTH0036 sodiumis a FAM labled ISTH0036 sodium (HY-158821A). ISTH0036 sodium is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 sodium suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 sodium exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 sodium can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases.
    FAM labled ISTH0036 sodium
  • HY-141489
    DSPE-PEG2000-Carboxy NHS sodium

    		Biochemical Assay Reagents Liposome Neurological Disease
    DSPE-PEG2000-Carboxy NHS sodium is a linker. DSPE-PEG2000-Carboxy NHS sodium enables conjugation of targeting peptides to lipid nanoparticles after their preparation. DSPE-PEG2000-Carboxy NHS (sodium) is applicable to the research of hereditary retinal degeneration .
    DSPE-PEG2000-Carboxy NHS sodium
  • HY-P992456
    SAR-443809

    		Complement System Cardiovascular Disease Endocrinology
    SAR-443809 is a selective alternative complement system inhibitor and monoclonal antibody targeting complement factor Bb. SAR-443809 blocks the cleavage of C3 and factor B by selectively binding to the activated form of factor Bb, with a KD of 7.3 nM for human factor Bb. SAR-443809 inhibits the amplification loop of the alternative complement pathway and C3 activation, reduces C3b deposition, and blocks the activation of pathways associated with intravascular and extravascular hemolysis. SAR-443809 can be used for the research of hematological and renal disorders mediated by abnormal alternative complement pathway .
    SAR-443809

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: